Clinical outcomes of hospital-acquired infection with Acinetobacter nosocomialis and Acinetobacter pittii

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 4172-4179

  Chusri, Sarunyou ^a,b   Chongsuvivatwong, Virasakdi ^a   Rivera, Jesabel I ^b   Silpapojakul, Kachornsakdi ^a   Singkhamanan, Kamonnut ^a   McNeil, Edward ^a   Doi, Yohei ^b  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM; CEFOPERAZONE PLUS SULBACTAM; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; FLUOROQUINOLONE; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULTAMICILLIN; TIGECYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ACINETOBACTER NOSOCOMIALIS; ACINETOBACTER PITTII; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; ASSAY; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII; CARBAPENEM SUSCEPTIBLE ACINETOBACTER BAUMANNII; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HOSPITAL INFECTION; HUMAN; LARVA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL RATE; THAILAND; ACINETOBACTER INFECTIONS; ANIMAL; ANTIBIOTIC RESISTANCE; CROSS INFECTION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOTH; PATHOGENICITY; TREATMENT OUTCOME;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AGED; ANIMALS; ANTI-BACTERIAL AGENTS; COHORT STUDIES; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; IMIPENEM; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOTHS; RETROSPECTIVE STUDIES; THIENAMYCINS; TREATMENT OUTCOME;

EID: 84903126411     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02992-14     Document Type: Article

References (26)

1. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538-582. http: //dx.doi.org/10.1128/CMR.00058-07.
2. Nemec A, Krizova L, Maixnerova M, van der Reijden TJ, Deschaght P, Passet V, Vaneechoutte M, Brisse S, Dijkshoorn L. 2011. Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly Acinetobacter genomic species 13TU). Res. Microbiol. 162:393-404. http://dx.doi.org/10.1016/j.resmic.2011.02.006.
3. Gerner-Smidt P, Tjernberg I, Ursing J. 1991. Reliability of phenotypic tests for identification of Acinetobacter species. J. Clin. Microbiol. 29:277-282.
4. Karah N, Haldorsen B, Hegstad K, Simonsen GS, Sundsfjord A, Samuelsen O. 2011. Species identification and molecular characterization of Acinetobacter spp. blood culture isolates from Norway. J. Antimicrob. Chemother. 66:738-744. http://dx.doi.org/10.1093/jac/dkq521.
5. Lee YC, Huang YT, Tan CK, Kuo YW, Liao CH, Lee PI, Hsueh PR. 2011. Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3 bacteraemia: comparison of clinical features, prognostic factors and outcomes. J. Antimicrob. Chemother. 66:1839-1846. http://dx.doi.org/10.1093/jac/dkr200.
6. Chuang YC, Sheng WH, Li SY, Lin YC, Wang JT, Chen YC, Chang SC. 2011. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clin. Infect. Dis. 52:352-360. http://dx.doi.org/10.1093/cid/ciq154.
7. Paterson DL. 2006. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin. Infect. Dis. 43(Suppl 2):S43-S48. http://dx.doi.org/10.1086/504476. (Pubitemid 44267139)
8. Maragakis LL, Perl TM. 2008. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis. 46:1254-1263. http://dx.doi.org/10.1086/529198. (Pubitemid 351589912)
9. Munoz-Price LS, Weinstein RA. 2008. Acinetobacter infection. N. Engl. J. Med. 358:1271-1281. http://dx.doi.org/10.1056/NEJMra070741.
10. Park YK, Jung SI, Park KH, Kim SH, Ko KS. 2012. Characteristics of carbapenem-resistant Acinetobacter spp. other than Acinetobacter baumannii in South Korea. Int. J. Antimicrob. Agents 39:81-85. http://dx.doi.org/10.1016/j. ijantimicag.2011.08.006.
11. Park KH, Shin JH, Lee SY, Kim SH, Jang MO, Kang SJ, Jung SI, Chung EK, Ko KS, Jang HC. 2013. The clinical characteristics, carbapenem resistance, and outcome of Acinetobacter bacteremia according to genospecies. PLoS One 8:e65026. http://dx.doi.org/10.1371/journal.pone.0065026.
12. Huang ST, Chiang MC, Kuo SC, Lee YT, Chiang TH, Yang SP, Ti Y, Chen TL, Fung CP. 2012. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J. Microbiol. Immunol. Infect. 45:356-362. http://dx.doi.org/10.1016/j.jmii.2011.12.009.
13. Zheng YL, Wan YF, Zhou LY, Ye ML, Liu S, Xu CQ, He YQ, Chen JH. 2013. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia. Am. J. Infect. Control 41:e59-e63. http://dx.doi.org/10.1016/j.ajic.2013.01.006.
14. Espinal P, Roca I, Vila J. 2011. Clinical impact and molecular basis of antimicrobial resistance in non-baumannii Acinetobacter. Future Microbiol. 6:495-511. http://dx.doi.org/10.2217/fmb.11.30.
15. Rongrungruang Y, Sawanpanyalert N, Chomdacha P, Surasarang K, Wiruchkul N, Kachintorn K, Tantilipikara P, Danchaivijitr S. 2013. Health-care associated infections in Thailand 2011. J. Med. Assoc. Thai. 96(Suppl 2):S117-S123.
16. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. 1988. CDC definitions for nosocomial infections, 1988. Am. J. Infect. Control 16:128-140. http://dx.doi.org/10.1016/0196-6553(88)90053-3.
17. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, Amyes SG, Livermore DM. 2006. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int. J. Antimicrob. Agents 27:351-353. http://dx.doi.org/10.1016/j.ijantimicag.2006.01.004.
18. La Scola B, Gundi VA, Khamis A, Raoult D. 2006. Sequencing of the rpoB gene and flanking spacers for molecular identification of Acinetobacter species. J. Clin. Microbiol. 44:827-832. http://dx.doi.org/10.1128/JCM.44.3.827-832. 2006.
19. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
20. Barry AL, Jones RN. 1988. Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination. J. Clin. Microbiol. 26:13-17. (Pubitemid 18049411)
21. United States Food and Drug Administration. 2013. Highlights of prescribing information (Tygacil). United States Food and Drug Administration, Silver Spring, MD.
22. Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC, Jr., Mylonakis E. 2009. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob. Agents Chemother. 53:2605-2609. http://dx.doi.org/10.1128/AAC.01533-08.
23. Wisplinghoff H, Paulus T, Lugenheim M, Stefanik D, Higgins PG, Edmond MB, Wenzel RP, Seifert H. 2012. Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J. Infect. 64:282-290. http://dx.doi.org/10.1016/j.jinf.2011. 12.008.
24. Schleicher X, Higgins PG, Wisplinghoff H, Korber-Irrgang B, Kresken M, Seifert H. 2013. Molecular epidemiology of Acinetobacter baumannii and Acinetobacter nosocomialis in Germany over a 5-year period (2005-2009). Clin. Microbiol. Infect. 19:737-742. http://dx.doi.org/10.1111/1469-0691.12026.
25. Yapa SWS, Li J, Patel K, Wilson JW, Dooley MJ, George J, Clark D, Poole S, Williams E, Porter CJ, Nation RL, McIntosh MP. 2014. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob. Agents Chemother. 58:2570-2579. http://dx.doi.org/10.1128/AAC.01705- 13.
26. OXA-51-like gene that is intrinsic to A. baumannii. Antimicrob. Agents Chemother. 56:1124-1127. http://dx.doi.org/10.1128/AAC.00622- 11.